What is the 13F Pro Quality Score for DAWN?

13F Pro ranks Day One Biopharmaceuticals, Inc. (DAWN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DAWN's current score at https://13fpro.ai/company/DAWN (free sign-up required for the full ranking).

Which hedge funds own the most DAWN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DAWN include BlackRock,, GLAZER CAPITAL,, FIL Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/DAWN as soon as new 13F filings post.

Where does 13F Pro source DAWN data?

All Day One Biopharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Day One Biopharmaceuticals, Inc. files with the SEC under CIK 1845337. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DAWN in?

Day One Biopharmaceuticals, Inc. (DAWN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DAWN research updated on 13F Pro?

DAWN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Day One Biopharmaceuticals, Inc.(DAWN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1845337 DAWN stock profile & AI dashboard →

13F Pro Quality Score

26.0/100

Rank #2,641 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

81.4/100

Profitability

0.1/100

Earnings Quality

47.4/100

Free Cash Flow

8.1/100

Institutional Flow

2.4/100

Revenue Scale

20.9/100

Dilution Risk

6.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DAWN Scores 27/100

exact factor attribution · 2026-09-09

DAWN's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.3 pts

82th pct

▲10

Earnings quality

-0.3 pts

47th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.2 pts

7th pct

Institutional flow

-2.4 pts

2th pct

Scale

-4.4 pts

21th pct

▼4

Capital efficiency

-5.0 pts

0th pct

Free cash flow

-6.3 pts

8th pct

Profitability

-7.5 pts

0th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DAWN Stock Analysis & AI Quality Score

Data updated 2026-09-09

AI stock analysis and institutional research for Day One Biopharmaceuticals, Inc. (DAWN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DAWN at 26.0/100 on a 32-signal composite quality model, placing it at rank #2,641 of 2,961 stocks — the bottom half of the AI-ranked universe. DAWN scores in the top quartile across revenue growth (81.4). Areas of concern include profitability (0.1) and institutional flow (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Day One Biopharmaceuticals, Inc. reports quarterly revenue of $53.7M, net income of $-107.2B, free cash flow of $-14.1M. Top institutional holders of DAWN by reported 13-F value include BlackRock, GLAZER CAPITAL, FIL Ltd, based on the most recent SEC filings. DAWN trades on the Nasdaq exchange and files with the SEC under CIK 1845337. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DAWN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Day One Biopharmaceuticals, Inc. directly from SEC EDGAR. Day One Biopharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 13 and 35 since 2025, currently 26.0 — a stable long-term trajectory across 51 quarterly and live scoring snapshots.

✦

Fun facts about Day One Biopharmaceuticals, Inc.

Quirks, history, and lore behind DAWN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in California · focused on developing targeted cancer therapies.
2
The Numbers
A small-cap biotech with minimal product revenue, funded largely by capital raises — the classic pre-commercial pharma model where the pipeline is the whole story.
3
The History
Founded around 2018, it moved quickly to build a focused oncology pipeline, going public on Nasdaq and zeroing in on RAS-addicted cancers — some of the hardest tumors to treat.
4
The Secret
Its lead program targets pediatric and young adult cancers driven by specific genetic alterations — a notoriously underserved patient population that big pharma has largely ignored.
5
The Lore
Its lead drug candidate tovorafenib received FDA approval in 2024 for pediatric low-grade glioma — a brain tumor — marking a rare win for kids with few other options.
6
The Giveaway
The company's very name declares its mission: every day is Day One for a child with cancer, and its ticker — DAWN — is about as on-the-nose as biotech branding gets.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2025

$53.7M

Net Income

Q4 2025

$-107.2B

Free Cash Flow

Q4 2025

$-14.1M

ROIC

Q4 2025

-24.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+20.6% YoY

$158.2MFY 2025

FY22 $0.00FY23 $0.00FY24 $131.2MFY25 $158.2M

Net Income

-112283.8% YoY

$-107.32BFY 2025

FY22 $-142.2MFY23 $-188.9MFY24 $-95.5MFY25 $-107.32B

Operating Income

+41.2% YoY

$-127.8MFY 2025

FY22 $-146.9MFY23 $-206.1MFY24 $-217.3MFY25 $-127.8M

EPS (Diluted)

-2.0% YoY

$-1.04FY 2025

FY22 $-2.17FY23 $-2.37FY24 $-1.02FY25 $-1.04

Total Assets

-12.9% YoY

$507.8MFY 2025

FY22 $349.1MFY23 $376.0MFY24 $582.8MFY25 $507.8M

Op. Cash Flow

-32.8% YoY

$-103.8MFY 2025

FY22 $-109.9MFY23 $-146.9MFY24 $-78.1MFY25 $-103.8M

Free Cash Flow

-29.6% YoY

$-104.1MFY 2025

FY22 $-109.9MFY23 $-147.1MFY24 $-80.3MFY25 $-104.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$158.2M +20.6%	$131.2M	$0.00	$0.00	—	—
Net Income	$-107.32B -112283.8%	$-95.5M +49.5%	$-188.9M -32.9%	$-142.2M +99.8%	$-72.75B -179508.5%	$-40.5M
Operating Income	$-127.8M +41.2%	$-217.3M -5.4%	$-206.1M -40.3%	$-146.9M -102.0%	$-72.7M -427.8%	$-13.8M
EPS (Diluted)	$-1.04 -2.0%	$-1.02 +57.0%	$-2.37 -9.2%	$-2.17 +53.0%	$-4.62 +37.0%	$-7.33
Total Assets	$507.8M -12.9%	$582.8M +55.0%	$376.0M +7.7%	$349.1M +20.4%	$289.8M +534.7%	$45.7M
Operating Cash Flow	$-103.8M -32.8%	$-78.1M +46.8%	$-146.9M -33.7%	$-109.9M -126.4%	$-48.5M -259.8%	$-13.5M
Free Cash Flow	$-104.1M -29.6%	$-80.3M +45.4%	$-147.1M -33.8%	$-109.9M -126.4%	$-48.5M -257.4%	$-13.6M

Get alerted when DAWN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Day One Biopharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DAWN

BlackRock, Inc.
$151.0M7,044,487 sh
GLAZER CAPITAL, LLC
$100.4M4,683,687 sh
FIL Ltd
$88.6M4,131,907 sh
Kryger Capital LLC
$83.5M3,896,485 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$79.8M3,723,131 sh
VANGUARD CAPITAL MANAGEMENT LLC
$72.0M3,357,684 sh
JPMORGAN CHASE & CO
$67.1M3,134,753 sh
STATE STREET CORP
$61.5M2,869,876 sh
BALYASNY ASSET MANAGEMENT L.P.
$56.3M2,625,235 sh
AQR Arbitrage LLC
$52.8M2,462,154 sh

Fund	Value	Shares
BlackRock, Inc.	$151.0M	7,044,487
GLAZER CAPITAL, LLC	$100.4M	4,683,687
FIL Ltd	$88.6M	4,131,907
Kryger Capital LLC	$83.5M	3,896,485
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$79.8M	3,723,131
VANGUARD CAPITAL MANAGEMENT LLC	$72.0M	3,357,684
JPMORGAN CHASE & CO	$67.1M	3,134,753
STATE STREET CORP	$61.5M	2,869,876
BALYASNY ASSET MANAGEMENT L.P.	$56.3M	2,625,235
AQR Arbitrage LLC	$52.8M	2,462,154

Companies Similar to DAWN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

FORA

Forian Inc.

AI score

Highly similar · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

SGMO

SANGAMO THERAPEUTICS, INC

AI score

Very similar · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

WGS

GeneDx Holdings Corp.

AI score

Similar quality profile · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

ARDX

ARDELYX, INC.

AI score

Similar quality profile · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

PSNL

Personalis, Inc.

AI score

Similar quality profile · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

SPRY

ARS Pharmaceuticals, Inc.

AI score

Similar quality profile

NVAX

NOVAVAX INC

AI score

Similar quality profile · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

QDEL

QuidelOrtho Corp

AI score

Similar quality profile · 1 shared holders

ORACLE INVESTMENT MANAGEMENT INC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DAWN on your watchlist

Track score changes the day Day One Biopharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DAWN a good stock to buy?

13F Pro's AI-powered analysis of Day One Biopharmaceuticals, Inc. (DAWN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DAWN are available on the DAWN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DAWN is classified as a mid company.

Which hedge funds own DAWN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DAWN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Day One Biopharmaceuticals, Inc.'s investment landscape.